Post-marketing surveillance of carfilzomib in Japanese patients with relapsed or refractory multiple myeloma.

Abstract

Aim: To evaluate the safety and effectiveness of carfilzomib in a real-world setting. Methods: A post-marketing surveillance of Japanese patients with relapsed or refractory multiple myeloma who received carfilzomib treatment was performed. Results: Overall incidences of adverse events of any grade, ≥grade 3 treatment-related adverse events and serious adverse events were 63.5, 44.6 and 37.7% of patients, respectively. No new safety findings were observed. Treatment-related adverse events of special interest (≥5%) were hematological toxicities, infectious disease, cardiac disorders (including cardiac failure, myocardial infarction and QT prolongation), renal disorders, liver failure or liver dysfunction, and hypertension or hypertensive crisis. The overall response rate was 46.5%. Conclusion: Carfilzomib was found to be a safe and effective treatment for relapsed or refractory multiple myeloma in Japanese patients.

• Authors: Akira Kawasaki, Hirokazu Murakami, Takaaki Chou, Masaru Matsushita, Masahiro Kizaki
• Journal: Future oncology (London, England) (Future Oncol) Vol. 18 Issue 24 Pg. 2661-2674 (Aug 2022) ISSN: 1744-8301 [Electronic] England
• PMID: 35815645 (Publication Type: Journal Article)

Chemical References

• Oligopeptides
• carfilzomib
• Dexamethasone

Topics

• Antineoplastic Combined Chemotherapy Protocols (adverse effects)
• Dexamethasone (therapeutic use)
• Humans
• Japan (epidemiology)
• Multiple Myeloma (drug therapy, epidemiology)
• Oligopeptides (adverse effects)
• Product Surveillance, Postmarketing